Trial Profile

Phase IA study of TNT009 in healthy volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sutimlimab (Primary)
Indications Autoimmune haemolytic anaemia
Focus Adverse reactions; Proof of concept

Most Recent Events

15 Jan 2016 New trial record
05 Jan 2016 According to True North Therapeutics media release, the company presented the results of this trial validating TNT009's proof-of-mechanism along with the overall development plan for TNT009 at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com